News
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy. The study — published May 11 in the New England Journal of Medicine — followed 751 people across the U.
Many are from the most deprived areas, and a significant number are neurodivergent or have other health conditions, a study ...
The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...
I worry about how these changes, which are occurring at the age of 13 or 14, might affect them later in life,” the study’s lead author said.
Individuals who lived with obesity as children are less likely to be in work or studying in their mid-20s than their peers, ...
Researchers used data-driven clustering to define 6 distinct obesity subtypes, offering a potential paradigm shift in how ...
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
IFLScience on MSN4d
Deleting "Mitch" Protein From Cells Could Make Humans "Immune" To ObesityMice whose MTCH2 proteins were silenced, or deleted, developed increased athletic capacity – they grew more muscle fibers, ...
President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...
Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...
The first five years of a child's life are crucial when it comes to preventing obesity in the future, according to researchers.Experts in the Netherlands found body mass index (BMI) at age six is a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback